PRESS RELEASE published on 04/21/2026 at 15:09, 5 months 9 days ago Original-Research: MaaT Pharma SACA (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research reaffirms Buy rating for MaaT Pharma SACA with a target price of €17 following FY25 results and pipeline update. No changes to core investment case First Berlin Equity Research BUY Rating MaaT Pharma SACA FY25 Results €17 Target Price
BRIEF published on 04/01/2026 at 07:35, 5 months 29 days ago MaaT Pharma Presents CHRONOS Study Results on Third-Line Acute GvHD MaaT Pharma Regulatory Review CHRONOS Study Acute GvHD Third-line Therapy
BRIEF published on 04/01/2026 at 07:35, 5 months 29 days ago MaaT Pharma publishes data on aGvH in "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 5 months 29 days ago MaaT Pharma publie des données sur l'aGvH dans "Bone Marrow Transplantation" MaaT Pharma EMA AGvH Xervyteg® CHRONOS
BRIEF published on 04/01/2026 at 07:35, 5 months 29 days ago MaaT Pharma présente les résultats de l'étude CHRONOS sur le traitement de troisième ligne de la GVHD aiguë MaaT Pharma Examen Réglementaire Étude CHRONOS GVHD Aiguë Traitement De Troisième Ligne
PRESS RELEASE published on 04/01/2026 at 07:30, 5 months 29 days ago Inside Information / Other news releases MaaT Pharma announces publication of retrospective data from CHRONOS study in Bone Marrow Transplantation Journal, presenting real-world outcomes of third-line systemic treatments for GI-aGvHD patients MaaT Pharma GI-aGvHD CHRONOS Study Retrospective Data Bone Marrow Transplantation
PRESS RELEASE published on 04/01/2026 at 07:30, 5 months 29 days ago Informations privilégiées / Autres communiqués MaaT Pharma publie des données rétrospectives de l'étude CHRONOS sur la maladie aiguë du greffon contre l'hôte (aGvH) dans Bone Marrow Transplantation. Résultats présentés au congrès annuel 2026 de l'EBMT MaaT Pharma Étude Bone Marrow Transplantation CHRONOS Maladie Aiguë Du Greffon Contre L'hôte
BRIEF published on 03/31/2026 at 07:35, 6 months ago MaaT Pharma: 2025 Revenue and Clinical Progress Revenue Funding Clinical Development MaaT Pharma Microbiothérapies
BRIEF published on 03/31/2026 at 07:35, 6 months ago MaaT Pharma : Chiffre d'Affaires 2025 et Progrès Cliniques Chiffre D'affaires Financement Développement Clinique MaaT Pharma Microbiothérapies
PRESS RELEASE published on 03/31/2026 at 07:30, 6 months ago Informations privilégiées / Information sur chiffre d’affaires annuel MaaT Pharma annonce ses résultats annuels pour l'année 2025 et fait le point sur ses activités. Avancées MaaT013, pipeline MaaT033 et MaaT034, accord de financement, trésorerie et perspectives de développement Développement Résultats Annuels Pipeline MaaT Pharma Accord Financement
Published on 10/01/2026 at 01:21, 5 hours 12 minutes ago Revival Gold Announces Filing of Final Base Shelf Prospectus
Published on 10/01/2026 at 01:00, 5 hours 33 minutes ago Algo Grande Copper Secures Five-Year Surface Access Agreement With Ejido Palos Chinos at the Adelita Project
Published on 09/30/2026 at 23:30, 7 hours 3 minutes ago Early Warning News Release Issued with Respect to the Acquisition of Securities of Cypher Metaverse Inc.
Published on 09/30/2026 at 20:35, 9 hours 58 minutes ago Fairplay Ventures Inc. Enters Into Definitive Agreement to Complete Qualifying Transaction With Ampere Metals Pty. Limited
Published on 09/30/2026 at 15:50, 14 hours 43 minutes ago Innodata Opens Motion-Capture AI Lab to Help Humanoids Move Like Humans
Published on 10/01/2026 at 05:05, 1 hour 28 minutes ago Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth
Published on 09/30/2026 at 23:23, 7 hours 10 minutes ago LM PAY S.A. publishes audited FY 2025 results: EBIT reaches PLN 12.4 million and exceeds preliminary result and guidance
Published on 09/30/2026 at 22:34, 7 hours 59 minutes ago The Change of Date of the Annual Report 2025 Publication
Published on 09/30/2026 at 22:05, 8 hours 28 minutes ago ADS-TEC Energy Reports First Half 2026 Results; Advances Gigawatt-Scale SKM Storage Project and Strengthens its Position to Scale Own & Operate Model
Published on 09/30/2026 at 22:05, 8 hours 28 minutes ago Abivax to Present Data on Obefazimod at United European Gastroenterology (UEG) Week 2026
Published on 09/30/2026 at 18:44, 11 hours 48 minutes ago Broadcast of the 5th edition of “On the way up”
Published on 09/30/2026 at 18:44, 11 hours 48 minutes ago Diffusion de la 5e édition de “On the way up”
Published on 09/30/2026 at 18:18, 12 hours 15 minutes ago Nombre total de droits de vote et d'actions composant le capital social
Published on 09/30/2026 at 18:15, 12 hours 18 minutes ago The Belgian State and ENGIE Group have agreed to extend the target date for concluding the Heads of Terms until 4 november 2026
Published on 09/30/2026 at 18:15, 12 hours 18 minutes ago L’État belge et le groupe ENGIE ont convenu de reporter au 4 novembre 2026 la date cible pour la conclusion des Heads of Terms
